★ Analysts see FY2027 revenue reaching $6.2B — +4.8% growth in a single year.
What Moves the Stock
01TiO2 pricing and demand trends: Global pigment supply-demand balance drives 45-50% of revenue, with pricing highly cyclical based on Chinese capacity additions and coatings/plastics end-market demand
02PFAS litigation developments: Multi-billion dollar legacy liabilities from PFOA/PFOS contamination create significant overhang, with settlements and regulatory actions driving material stock volatility
03Refrigerant transition momentum: Adoption rates of Opteon low-GWP products in automotive and HVAC markets as regulatory phase-downs of high-GWP HFCs accelerate globally
04Free cash flow trajectory: Company burned $1.0B FCF in TTM period; path to positive cash generation critical given 14.8x debt-to-equity ratio and refinancing needs
05Titanium Technologies (~45-50% of revenue): TiO2 pigments sold to coatings, plastics, and laminate manufacturers with pricing tied to global supply-demand dynamics
06Thermal & Specialized Solutions (~30-35%): Refrigerants including legacy HFCs and next-generation Opteon products for automotive, HVAC, and industrial applications
07Advanced Performance Materials (~15-20%): Teflon fluoropolymers, industrial films, and specialty chemicals for semiconductor, automotive, and industrial end markets
value/distressed - The stock trades at 0.5x sales with deeply negative equity metrics…
Elevated interest rate sensitivity due to 14.8x debt-to-equity ratio and negative free cash flow.
Watch on earnings: Global TiO2 pigment pricing indices and Chinese production capacity utilization rates, Automotive production volumes (North America, Europe, China) as proxy for coatings and refrigerant demand, Industrial Production Index as leading indicator for broad chemical demand.
One Sentence Summary:
Chemours: the story is balanced — tio2 pricing and demand trends: global pigment supply-demand balance drives 45-50% of revenue.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.